Overview

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
Phase:
Phase 1
Details
Lead Sponsor:
Haihe Biopharma Co., Ltd.
ShangHai HaiHe Pharmaceutical